Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 6

See more details

Referenced in 7 patents
Referenced in 1 Wikipedia pages
17 readers on Mendeley
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI115373

Nonsense mutations affect C1 inhibitor messenger RNA levels in patients with type I hereditary angioneurotic edema.

D Frangi, M Cicardi, A Sica, F Colotta, A Agostoni, and A E Davis 3rd

Division of Immunology, Children's Hospital, Boston, Massachusetts.

Find articles by Frangi, D. in: PubMed | Google Scholar

Division of Immunology, Children's Hospital, Boston, Massachusetts.

Find articles by Cicardi, M. in: PubMed | Google Scholar

Division of Immunology, Children's Hospital, Boston, Massachusetts.

Find articles by Sica, A. in: PubMed | Google Scholar

Division of Immunology, Children's Hospital, Boston, Massachusetts.

Find articles by Colotta, F. in: PubMed | Google Scholar

Division of Immunology, Children's Hospital, Boston, Massachusetts.

Find articles by Agostoni, A. in: PubMed | Google Scholar

Division of Immunology, Children's Hospital, Boston, Massachusetts.

Find articles by Davis, A. in: PubMed | Google Scholar

Published September 1, 1991 - More info

Published in Volume 88, Issue 3 on September 1, 1991
J Clin Invest. 1991;88(3):755–759. https://doi.org/10.1172/JCI115373.
© 1991 The American Society for Clinical Investigation
Published September 1, 1991 - Version history
View PDF
Abstract

Members of two unrelated families with type I hereditary angioneurotic edema (HANE) were found to have elevated levels of C1 inhibitor (C1INH) mRNA. DNA sequence analysis of PCR-amplified monocyte C1INH mRNA revealed normal and mutant transcripts, as expected in this disorder that occurs in heterozygous individuals. Single base mutations near the 3' end of the coding sequence were identified in affected members of each family. One mutation consisted of insertion of an adenosine at position 1304 which created a premature termination codon (TAA), whereas the second consisted of deletion of the thymidine at position 1298 which created a premature termination codon (TGA) 23 nucleotides downstream. These mutations are approximately 250 nucleotides upstream of the natural termination codon. Nuclear run-off experiments in one kindred revealed no difference in transcription rates of the C1INH gene between the patients and normals. C1INH mRNA half-life experiments were not technically feasible because of the prolonged half-life of the normal transcript. Dideoxynucleotide primer extension experiments allowed the differentiation of the normal and mutant transcripts. These studies showed that the mutant transcript was not decreased relative to the normal, and this therefore was at least partially responsible for the C1INH mRNA elevation. This elevation may be due to the decreased catabolism of the mutant transcript.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 755
page 755
icon of scanned page 756
page 756
icon of scanned page 757
page 757
icon of scanned page 758
page 758
icon of scanned page 759
page 759
Version history
  • Version 1 (September 1, 1991): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 6
  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 7 patents
Referenced in 1 Wikipedia pages
17 readers on Mendeley
See more details